Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775168 | 1.00 | HRH4 (0.54) | HRH4HRH3HRH2KITACVR1 | |
| SCHEMBL1775475 | 0.80 | PRKD1 (0.48) | HRH4HRH3KITACVR1PRKCQ | |
| SCHEMBL4789831 | 0.80 | PRKD1 (0.48) | HRH4HRH3KITACVR1PRKCQ | |
| SCHEMBL1774038 | 0.78 | HRH4 (0.65) | HRH4HRH3 | |
| SCHEMBL12321044 | 0.77 | FAAH (0.51) | HRH4 | |
| SCHEMBL1774043 | 0.76 | HRH4 (0.50) | HRH4HRH3HRH2 | |
| SCHEMBL17623223 | 0.76 | KIT (0.43) | HRH4KITACVR1PRKCQPRKCD | |
| SCHEMBL23523531 | 0.74 | KIT (0.43) | HRH4KITACVR1PRKCQPRKCD | |
| SCHEMBL20905784 | 0.74 | KIT (0.43) | HRH4KITACVR1PRKCQPRKCD | |
| SCHEMBL20898677 | 0.74 | KIT (0.43) | HRH4KITACVR1PRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| EP-1966162-A2 | PYRIMIDINE DERIVATIVES | Pfizer Limited (GB) | 2008-09-10 | — | — | EP | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
| WO-2007072163-A2 | PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | HRH4 184/4885HRH3 187/4885HRH2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.